NU6140 has been used to study its effect on transcription factors NANOG, OCT4 (organic cation/carnitine transporter 4) and SOX2(SRY-box 2), involved in pluripotency of human embryonic stem (hES) cells and embryonal carcinoma-derived (hEC) cells.
Biochem/physiol Actions
NU6140 is a CDK2 inhibitor with 10-36-fold selectivity over other CDK family members. NU6140 induces apoptosis and cell cycle arrest in cancer cells in the G2-M phase, and potentiates the cytotoxic effects of paclitaxel.
NU6140 is known to downregulate the expression of survivin protein, which possesses antiapoptotic activity and is generally overexpressed in cancer cells.